Market Overview

3 Reasons Why Nevro Corp. Was Downgraded By Morgan Stanley

Share:
3 Reasons Why Nevro Corp. Was Downgraded By Morgan Stanley
Related NVRO
75 Biggest Movers From Yesterday
7 Biggest Price Target Changes For Tuesday

The bullish case for Nevro Corp (NYSE: NVRO) — a medical device company that focuses on the treatment of chronic pain — no longer applies for three reasons, according to Morgan Stanley.

The Analyst

Morgan Stanley's David Lewis downgraded Nevro from Overweight to Equal-weight with a price target lowered from $94 to $88.

The Thesis

The bullish case for Nevro's stock was based on the following expectations, Lewis said in a Monday downgrade note:

All three catalysts now hold risk, Lewis said.

Nevro's commercial message of boasting clinically superior therapies isn't resonating as much as expected, while competing platforms like Abbott Laboratories (NYSE: ABT) Burst and Medtronic PLC (NYSE: MDT)'s Intellis have gained market traction, the analyst said. 

Expectations for expansion into new markets not only hasn't occurred, but Nevro is stuck in a "near-term catalyst void," Lewis said, giving the example of the company's diabetic neuropathy and non-surgical back pipelines. After timeline delays, the candidates are slated to begin enrollment in mid-2019, the analyst said.  

The superiority of Nevro's Senza could face challenges from Saluda's Evoke system in January 2019 or beforehand, Lewis said. The Saluda platform can be programmed to automatically adjust stimulation levels to a patient's preferred level and could be statistically superior to traditional SCS treatments, negatively affecting Nevro's commercial message, he said. 

Price Action

Shares of Nevro were sliding 9.44 percent at the time of publication Monday. 

Related Links:

Canaccord: Buy The Dip In Nevro After Disappointing Quarterly Report

Nevro Has A Multi-Billion Dollar Opportunity

Photo courtesy of Nevro Corp. 

Latest Ratings for NVRO

DateFirmActionFromTo
Nov 2018Bank of AmericaDowngradesBuyNeutral
Nov 2018Morgan StanleyDowngradesEqual-WeightUnderweight
Nov 2018Wells FargoMaintainsMarket PerformMarket Perform

View More Analyst Ratings for NVRO
View the Latest Analyst Ratings

Posted-In: chronic pain David LewisAnalyst Color Downgrades Health Care Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (ABT + MDT)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
BBCIBCUpgrades0.0
BKNGWells FargoUpgrades0.0
DARJP MorganUpgrades25.0
EEXBarclaysDowngrades12.0
HPCredit SuisseUpgrades65.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Hostess Brands Offers Sweet 20% Upside

The Truth About Reverse Mortgages